SOUTH SAN FRANCISCO, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that John Fowler, Chief Executive Officer, will present at the 2018 Wells Fargo Healthcare Conference on September 5, 2018, at 8:25 am PT.

The presentation will be webcast and may be accessed at the “Events & Presentations” section of the Company’s website at http://investors.kezarlifesciences.com/events . Kezar Life Sciences will maintain an archived replay of the webcast on its website for 30 days after the conference.

About Kezar Life Sciences

Based in South San Francisco, Kezar Life Sciences is a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. Kezar's lead product candidate, KZR-616, a first-in-class selective immunoproteasome inhibitor, has completed testing in healthy volunteers and is now enrolling a Phase 1b/2 clinical trial in lupus and lupus nephritis. In addition, Kezar is also leveraging its protein secretion pathway platform to discover and develop small molecule therapies targeting cancer and immuno-oncology. For more information, please visit www.kezarlifesciences.com .   

CONTACTS: Alex Gray, Burns McClellan, Inc., on behalf of Kezar Life Sciences 212-213-0006 agray@burnsmc.com